Which medication combination is known to decrease mortality in COPD?

The LABA - ICS combination, such as Advair (salmeterol/fluticasone), is recognized for its role in decreasing mortality in patients with Chronic Obstructive Pulmonary Disease (COPD). This is largely due to the synergistic effects of long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS); the LABA helps to relax and open the airways, improving airflow, while the ICS works to reduce inflammation in the airways.

The reduction of inflammation not only alleviates symptoms but also minimizes the frequency and severity of exacerbations, which are critical events that can lead to increased morbidity and mortality in COPD patients. Studies have shown that this combination therapy not only improves lung function and quality of life but also reduces the risk of exacerbations and overall death from COPD.

Other options, while useful in managing symptoms or providing short-term relief, do not have the same level of evidence supporting their effectiveness in reducing mortality. Short-acting beta agonists are generally used for acute symptom relief rather than long-term management. LAMA - LABA combos, while effective, have not demonstrated the same mortality benefit as the LABA - ICS combination in large-scale studies. Oral corticosteroids may be used for